Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $23.00 Consensus Target Price from Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have received an average rating of “Buy” from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $24.67.

STOK has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and set a $47.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 18th.

Stoke Therapeutics Stock Performance

NASDAQ STOK opened at $7.21 on Friday. The company has a market cap of $389.90 million, a PE ratio of -3.43 and a beta of 0.99. Stoke Therapeutics has a 52-week low of $7.06 and a 52-week high of $17.58. The firm’s 50 day moving average price is $9.32 and its 200-day moving average price is $11.19.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, analysts forecast that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now owns 63,962 shares in the company, valued at $554,550.54. This represents a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now directly owns 148,253 shares of the company’s stock, valued at $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock valued at $143,332 over the last ninety days. 11.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STOK. RTW Investments LP lifted its holdings in shares of Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock valued at $56,512,000 after buying an additional 471,240 shares during the period. Baker BROS. Advisors LP lifted its holdings in Stoke Therapeutics by 6.1% in the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock valued at $51,111,000 after acquiring an additional 265,395 shares during the period. Toronto Dominion Bank acquired a new position in Stoke Therapeutics in the fourth quarter valued at approximately $35,001,000. State Street Corp boosted its position in Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after purchasing an additional 137,145 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Stoke Therapeutics by 2.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock valued at $14,901,000 after purchasing an additional 38,446 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.